This is an old revision of this page, as edited by Vldscore (talk | contribs) at 15:46, 14 September 2011. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 15:46, 14 September 2011 by Vldscore (talk | contribs)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.029.698  |
| Chemical and physical data | |
| Molar mass | Mean MW = 4500 Daltons |
| (verify) | |
Nadroparin is a form of low molecular weight heparin sold by GSK under trademark Fraxiparine.
References
- GSK PRODUCT MONOGRAPH; http://www.gsk.ca/english/docs-pdf/Fraxiparine_2011.pdf
External links
- http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=483128
- http://www.mayoclinic.com/health/drug-information/DR600971
- Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A (2006). "A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study". Pharmacology. 78 (3): 136–43. doi:10.1159/000096484. PMID 17057417.
{{cite journal}}: CS1 maint: multiple names: authors list (link)
| Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antiplatelet drugs |
| ||||||||||||||
| Anticoagulants |
| ||||||||||||||
| Thrombolytic drugs/ fibrinolytics | |||||||||||||||
| Non-medicinal | |||||||||||||||
| |||||||||||||||
 | This drug article relating to the blood and blood forming organs is a stub. You can help Misplaced Pages by expanding it. |